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Hair and salivary cortisol and their 
relationship with lifestyle, 
mood and cognitive outcomes 
in premanifest Huntington’s 
disease
Travis Cruickshank1,2,3, Tenielle Porter1,2,4, Simon M. Laws1,2,4, Mel Ziman5,6 & 
Danielle M. Bartlett1,2*
Salivary cortisol dysrhythmias have been reported in some, but not all studies assessing 
hypothalamic–pituitary–adrenal (HPA) axis function in Huntington’s disease (HD). These differences 
are presumed to be due to environmental influences on temporal salivary cortisol measurement. 
Further exploration of HPA-axis function using a more stable and longer-term measure, such as 
hair cortisol, is needed to confirm earlier findings. This study aimed to evaluate hair and salivary 
cortisol concentrations and their associations with clinical and lifestyle outcomes in individuals with 
premanifest HD (n = 26) compared to healthy controls (n = 14). Participants provided saliva and hair 
samples and data were collected on clinical disease outcomes, mood, cognition, physical activity, 
cognitive reserve, sleep quality and social network size to investigate relationships between clinical 
and lifestyle outcomes and cortisol concentrations. Hair and salivary cortisol concentrations did 
not significantly differ between the premanifest HD and control groups. No significant associations 
were observed between hair or salivary cortisol concentrations and cognitive, mood or lifestyle 
outcomes. However, hair cortisol concentrations were significantly associated with disease outcomes 
in individuals with premanifest HD. Significant associations between hair cortisol concentrations and 
measures of disease burden and onset may suggest a potential disease marker and should be explored 
longitudinally in a larger sample of individuals with HD.
Hypothalamic–pituitary–adrenal (HPA) axis dysfunction has been suggested to be a key pathological feature and 
contributor to cognitive, mood and sleep disturbances in individuals with Huntington’s disease (HD)1,2. Studies 
in animal models and in individuals with HD have nevertheless yielded inconsistent findings, with some but not 
all investigations reporting acute cortisol  dysrhythmias3–5.
Early investigations noted a significant elevation in cortisol levels in individuals with manifest HD compared 
to healthy age and sex matched  controls6–8. However, more recent studies have been unable to replicate these 
earlier findings, consistently reporting no differences between individuals with HD and healthy controls. These 
inconsistent findings have been attributed to differences in sampling methods, as well as a failure to control 
environmental factors known to influence cortisol release.
To date most investigations have analysed cortisol release from collected blood, urine and saliva  samples6–8. 
Two of the existing studies have examined the cortisol awakening response (CAR)6,7, which refers to the sharp 
increase in cortisol secretion that occurs within the first 30–45 min following awakening in the  morning9. 
This biological phenomenon has been reported to display a consistent pattern in adults and exhibits good 
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intra-individual stability across two days, particularly when total morning cortisol output is examined (area under 
the curve, AUC)9–11. While valid and well-established, these methodological approaches only provide informa-
tion on short-lived stress, indicated by temporal cortisol release (< 24 h). Furthermore, while informative from a 
situational context, it is of utmost importance to evaluate longer-term or sustained stress, indicated by cumula-
tive cortisol release, particularly considering the potential impact on cognitive, mood and sleep  outcomes5,8,12, 
which are all negatively impacted in  HD13–15. It is therefore crucial to identify and evaluate the sensitivity of 
methodological approaches aimed at examining longer-term stress and associated cumulative cortisol release.
Recent studies in healthy and neurodegenerative populations indicate that hair is a useful biological sample 
for the analysis of longer-term, cumulative cortisol release. In a recent investigation, Pereira et al.16 noted signifi-
cantly higher hair cortisol concentrations in individuals with multiple sclerosis compared to healthy controls. 
Another investigation by Assayag et al.17 reported larger legion volumes and poorer cognitive performance in 
stroke victims with higher hair cortisol concentrations. Despite these positive findings, the utility of hair as a 
longer-term measure of cumulative cortisol release has not been investigated in individuals living with HD.
The primary aim of this investigation was to examine differences in hair and salivary cortisol concentrations 
between individuals with HD and healthy age and sex matched controls. Secondary aims of this investigation 
included: (1) examination of the environmental factors that significantly influence hair and salivary cortisol 
concentrations and (2) examination of associations between hair or salivary cortisol concentrations and cogni-
tive and mood outcomes.
Materials and methods
Study design. The aim of this cross-sectional study was to compare hair and salivary cortisol concentra-
tions between individuals with premanifest HD and healthy controls and to examine the relationships between 
hair or salivary cortisol concentrations and environmental, cognitive and mood measures in individuals with 
premanifest HD and healthy controls.
Study approval and patient consent. The study was carried out in accordance with the Declaration 
of Helsinki and was approved by the North Metropolitan Area Mental Health Service (2009_16), Edith Cowan 
University (13145) and Monash University (CF15/117-2015000058) Human Research Ethics Committees. All 
participants provided written informed consent prior to undertaking study assessments.
Participants. Twenty-six individuals with premanifest HD and 14 healthy controls participated in the study. 
Participants were recruited in Perth and Melbourne through the Enroll-HD study database, existing study data-
bases, clinicians and HD community organisations (premanifest HD) and via radio and newspaper advertise-
ment (healthy controls). Inclusion criteria for individuals with premanifest HD were as follows: (1) a cyto-
sine-adenine-guanine (CAG) repeat length of > 39; (2) a Unified Huntington’s Disease Rating Scale (UHDRS) 
Diagnostic Confidence Level (DCL) of ≤ 2; and (3) a UHDRS Total Motor Score (UHDRS-TMS) of < 5 for 
presymptomatic or > 5 for prodromal  HD18. Exclusion criteria for both groups were as follows: (1) concomitant 
neurological, cardiovascular, musculoskeletal, endocrine or metabolic disorders, (2) shift work, (3) recent or 
ongoing substance abuse, (4) current smoker, and (5) the inability to understand written and verbal English.
Study procedures. Participants collected saliva samples on two consecutive mornings. Hair samples (col-
lected by D.B) and cognitive measures (collected by T.C) were obtained from participants on one of the two 
saliva sampling days. Information regarding mood state and lifestyle activities was collected via self-report ques-
tionnaires during week of cortisol sampling. To maintain consistency in sampling and for pragmatic reasons, 
participants were asked to provide saliva samples on either two consecutive workdays or two consecutive non-
workdays, but not a mix of both, with non-workdays suggested. The UHDRS-TMS and DCL assessments were 
performed by a qualified clinician within four weeks of collection of other study data. CAG repeat length was 
provided by participants and other disease characteristics, such as estimated age at onset, estimated years to 
onset, disease burden score and CAG-age product score (CAPs) were calculated using previously established 
 methods19–21. Sociodemographic characteristics were collected via a questionnaire. Body mass index (BMI) was 
calculated by dividing the participant’s weight (in kg) by their height squared  (m2), with dual energy x-ray 
absorptiometry (DXA; Hologic Discovery A, Waltham, MA, USA) and wall mounted stadiometer (Model 222, 
Seca, Hamburg, DE) used to collect weight and height, respectively.
Cortisol measures. Hair cortisol. Hair samples were cut from the vertex posterior area of the head, as 
close to the scalp as possible. The first 3 cm of hair from the scalp end was used to assess cortisol concentra-
tions over the previous three months, based on the assumption that hair grows at a rate of approximately 1 cm 
per  month22. The hair washing and cortisol extraction procedures were carried out in line with a pre-existing 
 protocol23. Briefly, hair was washed twice in isopropanol and then left to air dry. The hair was weighed and 
transferred to 2 mL bead beating tubes containing 2.8 mm ceramic beads (Qiagen, Germany). Hair samples 
were ground using the Powerlyzer 24 homogeniser and then methanol was added to the samples and incu-
bated overnight (16 h) at room temperature for steroid extraction. Methanol was completely evaporated using a 
Speedvac Savant concentrator and dry samples were then eluted in 200 µL of phosphate buffered saline. Cortisol 
concentrations were determined using salivary cortisol enzyme-linked immunosorbent assay (ELISA) kits (IBL-
International, Hamburg, Germany), according to the manufacturer’s instructions. The intra-assay coefficients 
of variation (CV) were below 5% and the inter-assay CV was 13.5%. The functional sensitivity of the assay was 
reported to be 0.138 nmol/L.
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Salivary cortisol. Saliva samples were collected by participants in their own homes on two consecutive days. 
Participants were instructed on how to collect saliva samples during a face-to-face meeting with a study investi-
gator and were provided with detailed instructions on how and when to collect saliva samples. Participants were 
instructed to passively drool into four separate polypropylene collection tubes (SSI Bio) at four time points in the 
morning at 15, 30, 45 and 60 min following awakening for morning cortisol  analysis7. To avoid contamination of 
samples, participants were instructed to refrain from consuming alcohol 12 h prior and to avoid eating, drinking 
(with the exception of water) and brushing their teeth within the sampling time  frame7. Participants were pro-
vided with a diary to note down their time of awakening and when saliva samples were taken and to confirm that 
they had not consumed anything except water and had refrained from smoking, brushing their teeth and exer-
cising during the saliva sampling period. Participants stored saliva samples in their freezer until collection by a 
study investigator on the second day of sampling. Saliva samples were then stored at − 80 °C in the laboratory 
until analysis in duplicate using salivary cortisol ELISA kits (Salimetrics, USA) according to the manufacturer’s 
instructions. All intra-assay CVs were below 10% and the inter-assay CV was 7.3%. The functional sensitivity of 
the assay was reported to be 0.773 nmol/L. The CAR and area under the curve with respect to ground (AUC G) 
were calculated using the methods described by van Duijn et al.7. Briefly, CAR was calculated by averaging the 
cortisol concentrations between the 45- and 60-min time points and then subtracting the cortisol concentration 
of the first time point. AUC G was calculated using the trapezoid rule to determine total morning cortisol release 
for each day. The variation in cortisol AUC G values between sampling days was below 13% for both groups. Both 
the CAR and AUC G values were averaged across the two sampling  days7.
Affective measures. The 14-item Perceived Stress Scale was used to measure stress over the previous 
month. The Hospital Anxiety and Depression Scale (HADS) was used to measure anxiety and depression symp-
tomatology. The HADS is a 14-item questionnaire, with 7 items each relating to symptoms of anxiety and depres-
sion.
Cognitive measures. The Hopkins Verbal Learning Test-Revised (HVLT-R) was used to evaluate verbal 
learning and memory. The One Touch Stockings (OTS) assessment was used to evaluate planning and problem 
solving. The Trail Making Test (TMT; Parts A and B) was used to examine attention and cognitive flexibility. The 
Symbol Digit Modalities Test (SDMT) was used to assess processing speed.
Lifestyle measures. Lifestyle measures included self-report physical activity, cognitive reserve, social net-
work, sleep quality, smoking and alcohol consumption questionnaires. Physical activity was evaluated using 
the Minnesota Leisure Time Physical Activity Questionnaire. Cognitive reserve was calculated using values 
obtained from Cognitive Activity Scale, National Adult Reading Test, occupation and education status. Smoking 
status (packets per week) and alcohol consumption (standard drinks per week) were evaluated using a custom 
questionnaire. Social network size and diversity was evaluated using the Social Network Index. Sleep quality 
was measured using the Pittsburgh Sleep Quality Index. These measures were purposefully selected as they have 
been shown to be associated with measures of disease progression in  HD24,25 as well as cortisol regulation in the 
elderly and other clinical  populations26,27.
Statistical analysis. Based on sample size estimations, 29 participants were required per group (α = 0.05, 
1 − β = 0.8)28. However, as this study was ancillary to another study, recruitment was limited to the participant 
pool of the parent study, as well as other factors such as hair length, pigment loss and hair dying.
Rstudio (RStudio Team 2015) Version 1.2.5033 for Macintosh was used for all statistical analyses. Specific 
statistical packages within R were used where required and if not stated are available within the base R func-
tionality. Summary analyses of demographic, cognition and environmental variables provided means/counts 
and standard deviations/percentages stratified by disease classification (premanifest HD versus healthy controls. 
T-tests (age, perceived stress scale) and chi-squared tests (site, sex) were used to assess the differences between 
demographic measures.
Data normality was assessed using Shapiro–Wilk tests and analyses were undertaken accordingly. Hair cortisol 
and salivary cortisol data were not normally distributed. All other data fit the normal distribution. Analyses of 
covariance (ANCOVA), controlling for age and sex, were performed to assess differences in hair and salivary 
cortisol concentrations between individuals with premanifest HD and healthy controls. Associations between 
clinical classification, HD characteristics, cognition and environment, and cortisol levels (both hair and salivary) 
were investigated. Spearman’s partial correlations were used to assess relationships between variables, with age, 
sex and disease burden included as covariates, where appropriate.
Results
Demographic and clinical characteristics. Participants ranged in age from 22 to 70 (premanifest HD) 
and 21 to 58 (healthy controls). BMI ranged between 20.8 to 33.4 (premanifest HD) and 19.1 to 28.7 (healthy 
controls). Healthy controls exhibited significantly higher stress levels, as indicated by the Perceived Stress Scale, 
than individuals with premanifest HD (Table 1). No other differences were observed between groups across 
demographic and clinical characteristics.
Between-group comparisons of hair and salivary cortisol concentrations. No differences were 
observed in cumulative hair cortisol or temporal salivary cortisol concentrations between premanifest HD and 
healthy control groups (Table 2).
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Between-group comparisons of cognitive and lifestyle outcomes. Individuals with premanifest 
HD performed significantly worse than healthy controls on measures of verbal learning and memory (HVLT-R), 
planning and problem solving (OTS), attention (TMT-A), cognitive flexibility (TMT-B) and processing speed 
(SDMT; Table 2). No other significant differences were observed for cognitive or lifestyle measures between the 
groups.
Correlations between hair and salivary cortisol concentrations and cognitive and lifestyle 
measures. Significant associations were noted between hair cortisol concentrations and clinical disease out-
comes in the premanifest HD group (Table 3). In particular, these associations were observed for disease bur-
den score and the estimated number of years to disease onset. No other significant associations were observed 
between cumulative hair or temporal salivary cortisol concentrations and clinical, cognitive or lifestyle measures 
in the premanifest HD or healthy control groups.
Discussion
Abnormalities in cortisol release have been reported previously in individuals with HD and have been suggested 
to be an indicator of hypothalamic–pituitary–adrenal (HPA) axis  pathology29,30. However, these studies used 
salivary cortisol as the principal output, which is prone to temporal changes in response to environmental and 
psychological stimuli. Accumulative cortisol in hair has been proposed as a measure of longer-term or sustained 
stress. Here, we examined, for the first time, hair cortisol concentrations in individuals with premanifest HD 
in comparison to healthy controls. Furthermore, we assessed the relationships between cumulative cortisol in 
hair and shorter-term temporal salivary cortisol and clinical, cognitive and lifestyle measures in individuals 
with premanifest HD. We report no significant differences between groups in longer-term or sustained stress, as 
indicated by cumulative hair cortisol concentrations. Furthermore, we note no significant associations between 
hair or salivary cortisol concentrations and environmental and clinical outcomes.
Previous studies have noted significant differences in saliva cortisol concentrations between individuals with 
HD and healthy  controls7,8. We were unable to replicate these earlier findings in our cohort. In particular, we 
found no differences in hair and salivary cortisol concentrations between individuals with premanifest HD and 
healthy controls. This was unexpected. Given that regulation of the CAR, and cortisol release in general, involves 
the hippocampus, amygdala, prefrontal cortex and suprachiasmatic  nucleus31,32 and considering the known 
pathological changes to these structures to varying extents in  HD29,30,33,34, it was anticipated that differences 
between hair and salivary cortisol metrics would be observed. The reason for the discrepancy in findings is not 
known, however it is noteworthy that, contrary to previous  reports7,35, stress levels were significantly lower in 
the premanifest HD group than in healthy controls. Interestingly, cumulative hair cortisol concentrations were 
Table 1.  Demographic and clinical information for individuals with premanifest HD and healthy controls. 
Data is reported as mean (standard deviation) unless otherwise stated. T-tests and chi-squared tests were 
used for comparisons between groups. Results were considered significant at p < 0.05* (bolded values). BMI 
body mass index, UHDRS-TMS unified Huntington’s disease rating scale total motor score, DCL diagnostic 
confidence level, CAGn cytosine-adenine-guanine trinucleotide repeat number, CAPs scaled CAG-age product 
score, HADS hospital anxiety and depression scale.
Premanifest HD (n = 26) Healthy controls (n = 14) p value
Sociodemographic characteristics
Age 43.85 (12.19) 42.21 (10.63) 0.676
Female, n (%) 21 (80.8%) 13 (92.9%) 0.578
Ethnicity
 Caucasian, n (%) 25 (96.2%) 11 (78.6%) 0.123
BMI 25.81 (3.38) 25.18 (2.98) 0.584
Medication Use
 Glucocorticoids, n (%) 0 (0%) 0 (0%) 1.000
 Contraceptives, n (%) 6 (23.1%) 3 (21.4%) 0.855
Disease characteristics
UHDRS-TMS 3.96 (6.89) – –
DCL 0.3 (0.7) – –
CAGn 43.15 (3.00) – –
Estimated age at onset 54.97 (11.91) – –
Estimated years to onset 5.81 (7.73) – –
Disease burden score 308.87 (74.11) – –
CAPs 0.9 (0.18) – –
Neuropsychiatric characteristics
Perceived stress scale 16.28 (6.69) 22.79 (7.03) 0.007*
HADS (total score) 6.77 (5.62) 10.36 (6.7) 0.080
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found to be associated with disease burden score and the estimated number of years to disease onset, initially sug-
gesting that it may be a potential candidate for a biological marker of disease progression. However, considering 
no differences were observed in cumulative hair cortisol concentrations between the groups, this may represent 
a coincidental finding. In addition, CAR metrics did not appear to be a sensitive marker in this group, despite 
earlier  findings7. Nevertheless, both cortisol measurements should be evaluated longitudinally to definitively 
assess whether they change over time as the disease progresses.
Associations between clinical outcomes, including mood and cognitive outcomes, and temporal salivary 
cortisol release have been reported previously in  HD5,8. Shirbin et al. reported associations between short-term 
salivary cortisol release and depressive symptomology and performance on verbal learning and memory  tasks5,8. 
These earlier findings were not reflected in the present study. In particular, no associations were observed between 
hair or salivary cortisol release and cognitive and mood outcomes in individuals with HD. It is possible that these 
relationships do not arise until late in the disease course, where symptoms of the disease progressively emerge.
Preclinical studies have previously documented positive effects of environmental enrichment on HPA-axis 
structures, including the adrenal glands, which are involved in the regulation of  glucocorticoids36. Studies in 
older adults and other clinical populations, including schizophrenia, have additionally reported a negative effect 
of unhealthy lifestyle behaviours, such as physical inactivity and social isolation on cortisol  regulation27,37. It was 
therefore hypothesised that lifestyle factors, particularly physical activity, cognitive reserve and social network 
size would be negatively associated with cortisol levels such that greater physical activity, cognitive reserve and 
social network size would be associated with lower cortisol levels. Our findings did not support this hypothesis, 
with no associations observed between hair or salivary cortisol levels and any of the lifestyle factors. However, it 
should be noted that this study adopted a cross-sectional design, it is possible that associations between cortisol 
and lifestyle outcomes may arise over time, particularly as the disease advances.
Table 2.  Differences in cognition and lifestyle data between individuals with premanifest HD and healthy 
controls. CAR cortisol awakening response, AUC G area under the curve with respect to ground, PSQI 
Pittsburgh Sleep Quality Index. a Excessive alcohol consumption defined as greater than 14 standard alcoholic 
beverages per week. Data is presented as mean (standard deviation) unless otherwise stated. T-tests and 
chi-squared tests were used for comparisons between groups. Results were considered significant at p < 0.05* 
(bolded values).
Premanifest HD (n = 26) Healthy controls (n = 14) p value
Cortisol measures
Hair cortisol (nmol/L) 2.66 (2.06) 4.08 (4.71) 0.230
Salivary cortisol (nmol/L)
 T1 (+ 15 min post awakening) 11.36 (4.00) 11.85 (3.71) 0.619
 T2 (+ 30 min post awakening) 14.27 (4.77) 13.97 (5.17) 0.803
 T3 (+ 45 min post awakening) 14.12 (3.55) 14.34 (5.35) 0.815
 T4 (+ 60 min post awakening) 12.68 (3.73) 13.04 (4.15) 0.838
Estimated CAR 2.04 (3.58) 1.84 (3.96) 0.977
AUC G (nmol/L) 40.41 (10.86) 40.75 (13.39) 0.890
Cognitive measures
Hopkins verbal learning test-revised
 Total recall 25.38 (5.06) 31.5 (2.88) < 0.001*
 Delayed recall 9.42 (1.96) 11.43 (0.94) 0.001*
 Retention 93.91 (9.81) 97 (7.32) 0.309
One touch stockings
 Choices to correct 1.38 (0.42) 1.17 (0.12) 0.064
 Latency to correct 12,947.35 (5554.26) 14,809.08 (8109.34) 0.396
 Latency to first choice 21,183.97 (8629.6) 27,032.33 (16,006.93) 0.140
 Problems solved on first choice 17.81 (4.77) 20.64 (1.86) 0.040*
Trail making test
Part A 29.91 (13.87) 19.43 (4.83) 0.010*
Part B 67.55 (30.96) 44.64 (12.09) 0.012*
Symbol digit modalities test 53.04 (14.2) 63.64 (5.99) 0.011*
Lifestyle measures
Smoking, n (%) 3 (11.5%) 0 (0.0%) 0.505
Alcohol consumption, n (%)a 1 (3.8%) 2 (14.3%) 0.639
Metabolic equivalents (METs) 4084.65 (7064.6) 6685.86 (8048.19) 0.297
Cognitive reserve 0.01 (2.96) 1.21 (2.5) 0.224
Number of people in social network 25.5 (25.49) 30.36 (21.82) 0.560
PSQI global score 5.8 (3.08) 5.93 (2.73) 0.897
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:5464  | https://doi.org/10.1038/s41598-021-84726-4
www.nature.com/scientificreports/
Several limitations need to be considered when interpreting our findings. First, this was a cross-sectional 
investigation of associations between cortisol concentrations and clinical and environmental outcomes, subse-
quently causation cannot be determined. Second, this study had a relatively small sample of participants with 
premanifest HD and healthy age and sex matched controls. Therefore, it is not known whether associations 
between cortisol and clinical and environmental outcomes manifest later in the disease course, which has been 
described, albeit only in a few studies previously. It is important to note that this study consisted predominantly 
of female participants. While this was not intended, this may bias the results, particularly as females may have 
different cortisol rhythms to males and these are influenced by menstrual events. It is also noteworthy that the 
timing of saliva sampling was self-reported, which can be influenced by responder and recall bias. This bias might 
be overcome in the future by using tubes with timing caps, which has been suggested by Stalder et al.38. Finally, 
cortisol has been shown to be influenced by seasonal changes. Participants in this study were sampled in Aus-
tralia only (Melbourne and Perth) during spring, when there is progressively greater sunlight and better weather 
conditions. This may be in contrast to previous studies that may have taken cortisol samples in winter months, 
when there is less sunlight and poorer weather conditions. Future studies are needed to evaluate changes in hair 
and salivary cortisol, and the potential associations with clinical and environmental outcomes, longitudinally.
Despite the abovementioned limitations, it is important to note that this is the first study to investigate 
longer-term or sustained stress as indicated by cumulative cortisol concentrations in hair in individuals with 
Table 3.  Spearman’s partial correlations between clinical variables and hair and salivary cortisol in individuals 
with premanifest HD. Data was assessed using Spearman’s partial correlations. Age, sex and disease burden 
score were controlled for in all analyses, except for correlations between hair and salivary cortisol and disease 
burden score, in which age and sex were control variables. Correlations were considered significant at p < 0.05  
(bolded values) and rs-values were considered small, medium and large at rs < 0.30, rs > 0.30 to < 0.5 and rs > 0.5, 
respectively. CAGn cytosine-adenine-guanine trinucleotide repeat number, UHDRS-TMS Unified Huntington’s 
Disease Rating Scale Total Motor Score, CAPs scaled CAG-age product score, BMI body mass index, HADS 
Hospital Anxiety and Depression Scale, METs metabolic equivalents, PSQI Pittsburgh Sleep Quality Index.
Outcome
Hair cortisol Salivary cortisol
rs-value p value rs-value p value
Clinical characteristics
CAGn 0.05 0.83 − 0.28 0.22
UHDRS-TMS − 0.13 0.56 0.37 0.10
DBS 0.52 0.01* − 0.15 0.51
CAPs − 0.17 0.45 0.42 0.06
Estimated years to onset 0.44 0.04* − 0.11 0.63
Estimated age of onset 0.19 0.39 0.19 0.41
BMI − 0.23 0.32 0.19 0.43
HADS
 Anxiety − 0.05 0.82 0.17 0.46
 Depression − 0.12 0.61 − 0.17 0.46
 Total score − 0.11 0.63 0.07 0.76
Cognitive measures
Hopkins verbal learning test-revised
 Total recall − 0.26 0.23 − 0.16 0.48
 Delayed recall − 0.20 0.37 − 0.31 0.17
 Retention 0.04 0.86 − 0.41 0.07
One touch stockings
 Choices to correct 0.01 0.97 0.13 0.57
 Latency to correct 0.15 0.50 0.26 0.25
 Latency to first choice 0.00 0.99 0.33 0.12
 Problems solved on first choice 0.15 0.71 − 0.06 0.82
Trail making test
 Part A 0.15 0.52 0.02 0.94
 Part B 0.21 0.22 0.16 0.53
Symbol digit modalities test − 0.16 0.44 − 0.39 0.08
Lifestyle measures
Monthly METs − 0.07 0.76 − 0.09 0.70
Cognitive reserve − 0.07 0.76 0.40 0.08
Number of people in social network − 0.13 0.48 − 0.11 0.58
PSQI global score 0.17 0.47 − 0.19 0.42
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premanifest HD. Furthermore, this is the first study to evaluate associations between longer-term or sustained 
stress, indicated by cumulative cortisol release, and shorter-lived stress, indicated by temporal cortisol release, 
and environmental outcomes in individuals with premanifest HD. In contrast to previous findings, we observed 
no differences in hair or salivary cortisol concentrations between individuals with premanifest HD or healthy 
controls. In addition, we found no associations between cortisol concentrations and mood, cognitive and environ-
mental outcomes. Small to moderate associations were found between hair cortisol concentrations and measures 
of disease burden, however, as no differences were observed between groups this is likely a spurious finding. 
Nevertheless, this latter finding provides impetus for further investigation of longer-term or sustained cortisol 
and associations with clinical and environmental outcomes longitudinally.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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